Health Catalyst Reports $111M Q1 Net Loss, $95.5M Goodwill Impairment; Announces Further 9% Workforce Reduction
summarizeSummary
Health Catalyst reported a significantly widened Q1 net loss of $111 million, including a $95.5 million goodwill impairment, alongside an 11% revenue decline and plans for a further 9% workforce reduction.
check_boxKey Events
-
Massive Net Loss
Reported a net loss of $111.0 million for Q1 2026, a significant increase from $23.7 million in Q1 2025.
-
Substantial Goodwill Impairment
Incurred a $95.5 million non-cash goodwill impairment charge in Q1 2026, primarily due to declines in stock price and market capitalization.
-
Revenue Decline
Total revenue decreased by 11% year-over-year to $70.8 million, with professional services revenue down 24% and technology revenue down 4%.
-
Further Workforce Reduction Planned
Authorized 'Project Nexus,' a 9% global workforce reduction in Q2 2026, eliminating approximately 100 positions, with expected charges of at least $4.0 million.
auto_awesomeAnalysis
Health Catalyst reported a net loss of $111.0 million for Q1 2026, a substantial increase from $23.7 million in Q1 2025. This significant loss includes a $95.5 million goodwill impairment charge, reflecting a major write-down of asset values due to declines in stock price and market capitalization. Total revenue decreased by 11% year-over-year to $70.8 million, driven by a 24% drop in professional services revenue and a 4% decline in technology revenue. The company also announced 'Project Nexus,' a subsequent event involving a 9% workforce reduction in Q2 2026, following previous restructuring plans. These financial results and operational changes highlight severe ongoing challenges, including significant ARR at risk from platform migrations and a deteriorating balance sheet, which could impact the company's long-term viability.
At the time of this filing, HCAT was trading at $1.57 on NASDAQ in the Technology sector, with a market capitalization of approximately $101.5M. The 52-week trading range was $0.96 to $4.74. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.